Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A study to establish the efficacy of QBX258 in patients with moderate to severe asthma
Change in Asthma Control Questionnaire score
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructive pulmonary disease
The primary objective is to demonstrate superiority of indacaterol (150 µg) versus placebo with respect to 24 h post-dose (trough) forced expiratory volume in 1 second (FEV1) after 12 weeks of treatme...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis
To evaluate the efficacy of different loading dose regimens of AIN457 at 6 weeks (part 1 ) and 12 weeks (part 2) based on the proportion of patients achieving ACR20 response
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes
To confirm the efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that the hemoglobin A1c (HbA1c) reduction with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) is superior to tha...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A study to evaluate disease control and safety in patients with RRMS switching from natalizumab to fingolimod
To evaluate disease control during different lengths of treatment transition from natalizumab to fingolimod from the last natalizumab infusion through 8 weeks of fingolimod treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line therapy in postmenopausal women with advanced breast cancer
To demonstrate superior efficacy of the combination therapy of RAD001 10mg daily plus letrozole 2.5 mg daily versus the combination of placebo plus letrozole 2.5 mg daily in postmenopausal women with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
A double-blind, randomized, placebo-controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo
To evaluate the change from baseline in 72-hour serum phosphate of different doses of SBR759 versus placebo over 4 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis
To establish a pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD)relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses and to evaluate the impact...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CFZ533
• To assess the safety and tolerability of multiple intravenous infusion of CFZ533 in patients with primary Sjögren’s syndrome as measured by adverse events (AEs) • To compare the effect of multiple ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 4 ans
Study to evaluate the efficacy and safety of glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed - dose combination regarding symptoms and health status in patients with moderate COPD switching from treatment with any standard COPD regimen
• To show the superiority of glycopyrronium (50 μg o.d.) vs. short-acting bronchodilators (SABA and/or SAMA as monotherapy or in free or FDC) on FEV1 at week 12. • To show the non-inferiority of gly...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
21
22
23
24
25
26
27
28
29
30
Suivant